SURVYR

XNCR

Xencor, Inc.
$29.99
+$0.00 (0.00%)Oct 28 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-27%+8%+44%+79%+115%Oct 2025Oct 2026Apr 202652w high $30.6152w low $10.38
XNCRSPY
Wall St. Highest PT $46.00 (+53.4%) Wall St. Avg PT $31.42 (+4.8%)
$10$20$29$38$47POC $13Hi $46Avg $31
Underwater Drawdown %Max DD -42.6%Current 0.0%
0.0%-42.6%
Relative Strength vs SPY+96.2% vs SPYOutperforming
+111%0%-111%
1W
+$4.83 (19.20%)
1M
+$4.39 (17.15%)
3M
+$10.46 (53.56%)
6M
+$18.37 (158.09%)
YTD
+$14.68 (95.89%)
1Y
+$15.74 (110.46%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
14 analysts · mean score 1.50
1 = Strong Buy · 5 = Sell
Strong Buy321%
Buy964%
Hold214%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$29.99
Average target$31.42
+$1.43 (+4.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$20.00
Median$30.00
High$46.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-21 · Wedbush reiterated Outperform on XNCR
Reiterated
2026-09-28 · Truist Securities reiterated Buy on XNCR
Reiterated
2026-09-21 · B of A Securities reiterated Neutral on XNCR
Reiterated
2026-09-11 · Barclays reiterated Overweight on XNCR
Reiterated
2026-09-03 · JP Morgan reiterated Neutral on XNCR
Reiterated
2026-09-01 · Raymond James reiterated Strong Buy on XNCR
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.9B
P/E (next 12 months, estimated)-7.1
52-week range$10.38 – $30.61
Revenue growth (latest quarter vs a year ago)+17.5%
Dividend yieldNo dividend
Analyst consensusStrong Buy (12)
Average analyst price target$31.42 (+5%)

What they do

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
86th percentile in sector
A-
12-1 return: +69.6%
Percentile within its GICS sector across the S&P 1500.
Growth
77th percentile in sector
B+
Revenue growth (YoY): +17.5%
Percentile within its GICS sector across the S&P 1500.
Value
Not enough data yet
–
Forward E/P: – · EBITDA/EV: –
Percentile within its GICS sector across the S&P 1500.
Profitability
4th percentile in sector
F
Profit margin: -155.6% · Return on equity: -29.1%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

XNCR earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Time not confirmed
EPS consensus-$0.40 range -$1.21–$0.22
Revenue consensus$59.1M 13 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.29est -$0.84+65.6%Above estimates
May 6, 2026-$1.71est -$0.75−129.0%Below estimates
Feb 25, 2026-$0.09est -$0.58+84.6%Above estimates
Nov 5, 2025-$0.08est -$0.70+88.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 07:25:33 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.710.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$51.2M+17.5%
2026-03-31$4.5M–
2025-12-31$28.2M–
2025-09-30$21.0M–
2025-06-30$43.6M–

News & catalysts

More news
Xencor Shares Rise Pre-Bell After Kidney Cancer Trial Shows 45.5% Response Rate
MT Newswires · Oct 26
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Business Wire · Oct 25
Is Xencor (XNCR) A Bargain After Its XmAb819 Phase 1 Update?
Simply Wall St. · Oct 19
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Business Wire · Oct 19
Raymond James Updates Healthcare Top Picks for October
Investing.com · Oct 01
Rating changes
Reiterated
2026-10-21 · Wedbush reiterated Outperform on XNCR
Reiterated
2026-09-28 · Truist Securities reiterated Buy on XNCR
Reiterated
2026-09-21 · B of A Securities reiterated Neutral on XNCR
Reiterated
2026-09-11 · Barclays reiterated Overweight on XNCR
Reiterated
2026-09-03 · JP Morgan reiterated Neutral on XNCR
Reiterated
2026-09-01 · Raymond James reiterated Strong Buy on XNCR

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-26 07:25:33 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026